CASTRATION-INDUCED LYMPHOCYTOSIS IN PROSTATE-CANCER - POSSIBLE EVIDENCE FOR GONAD THYMUS ENDOCRINE INTERACTION IN MAN

被引：11

作者：

OLIVER, RTD

JOSEPH, JV

GALLAGHER, CJ

机构：

[1] Medical College, Royal London Hospital

来源：

UROLOGIA INTERNATIONALIS | 1995年 / 54卷 / 04期

关键词：

PROSTATE CANCER; GONAD THYMUS; INTERACTION;

D O I：

10.1159/000282729

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Prompted by evidence from animal studies that castration produces lymphocytosis associated with thymic hyperplasia, this paper has reviewed serial lymphocyte levels in patients with prostate cancer undergoing hormone treatment. On day 7, 5 of 12 patients (58%) showed diminished circulating lymphocyte levels (compared to day 0) reflecting the surge of testosterone after treatment with LHRH analogues, while on day 28 a reversal had occurred and 13 of 17 (77%) had increased lymphocytes (compared to day 0). Possible relevance of these observations to defining a subgroup of patients with hormone-sensitive cancer who might benefit from immunotherapy is discussed.

引用

页码：226 / 229

页数：4

共 15 条

[1]

Oliver R.T.D., The clinical potential of interleukin-2, Br J Cancer, 58, pp. 405-409, (1988)

[2]

Horoszewicz J.S., Murphy G.P., An assessment of the current use of human interferons in therapy of urological cancers, J Urol, 142, pp. 1173-1180, (1989)

[3]

Oliver R.T.D., Crosby D., Nouri A., Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy, Br J Cancer, 64, pp. 934-937, (1989)

[4]

Grossman C.J., Interactions between the gonadal-steroids and the immune system, Science, 227, pp. 257-261, (1985)

[5]

Chapman N., Twigg G.I., Studies on the thymus gland of British cervidal, particularly muntzac and fallow deer, J Zool Lond, 222, pp. 653-675, (1990)

[6]

Fitzpatrick F.T.A., Kendall M.D., Wheeler M.J., Reappearance of thymus in ageing male rats treated for one month with a stable analogue of luteinizing hormone releasing hormone, J Endocrinol, 106, pp. R17-R19, (1985)

[7]

Parmar H., Lightman S.L., Allen L., Randomised controlled study of orchidectomy vs long-acting D-TRP-6-LHRH microcapsules in advanced prostatic carcinoma, Lancet, 2, (1985)

[8]

O'Brien A., Hibberd M., Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer, J Int Med Res, 18, pp. 57-68, (1990)

[9]

Sperandio P., Tomio P., Oliver R.T.D., Gonadal atrophy as a cause of thymic hyperplasia after chemotherapy, Br J Cancer, (1995)

[10]

Crawford E.D., Eisenberger M.A., McCleod D.G., A controlled trial of leuprolide with and without flutamide in prostatic carcinoma, N Engl J Med, 321, pp. 419-424, (1989)

← 1 2 →